ArticleScientific reports2020

Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients.

Bharathi M Rajamani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.